Literature DB >> 6320601

Purine metabolizing enzymes in lymphocytes from patients with solid tumors.

J Mejer, S Hørbov, P Nygaard.   

Abstract

The activities of five clinically important enzymes of purine metabolism have been determined in lymphocytes from 62 patients with various types of solid tumors. The activity of purine nucleoside phosphorylase was increased in all patient groups studied, i.e. small cell bronchogenic carcinoma (n = 30), carcinoma of the breast (n = 17) and other tumors (n = 15), compared to cells form normal donors. Activities of adenosine deaminase, adenine phosphoribosyltransferase (APRT), hypoxanthine (guanine) phosphoribosyltransferase (HGPRT), and 5'-nucleotidase (5'-NUC) vary little from control values, except for lower levels of APRT in lymphocytes from patients with carcinoma of the breast. In patients with small cell bronchogenic carcinoma, enzyme levels were also determined in granulocytes, where increased APRT activity was found. Following cytostatic treatment of these patients, significant decreases were seen in lymphocytic HGPRT and 5'-NUC activities.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6320601     DOI: 10.1111/j.0954-6820.1984.tb04963.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

1.  Segregation of a t(3;20) translocation through three generations resulting in unbalanced karyotypes in six persons.

Authors:  K B Nielsen; N Tommerup; B Jespersen; P Nygaard; L Kleif
Journal:  J Med Genet       Date:  1986-10       Impact factor: 6.318

Review 2.  Molecular epigenetic dynamics in breast carcinogenesis.

Authors:  Aadrita Hazra; Pritha Bose; Priyashree Sunita; Shakti P Pattanayak
Journal:  Arch Pharm Res       Date:  2021-08-15       Impact factor: 4.946

3.  Enzyme activities controlling adenosine levels in normal and neoplastic tissues.

Authors:  D Vannoni; A Bernini; F Carlucci; S Civitelli; M C Di Pietro; R Leoncini; F Rosi; A Tabucchi; G Tanzini; E Marinello
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.